Emcure Pharma shares at record high! Stock soars 10% today, up 16% in 2 days: More rally ahead? Buy, sell or hold?
LiveMint

Emcure Pharmaceuticals shares hit a record high after rising 16% in two
sessions, following strong Q2FY27 results. Profit increased 29% and revenue
grew 24%. Jefferies and Kotak retained Buy ratings, citing growth prospects
and setting target prices of ₹2,500 and ₹2,450.






